

Synonym

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib

Source

Mouse LRRC15, His Tag(LR5-M5225) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 536 (Accession # [Q80X72-1](#)).

Molecular Characterization

LRRC15(Tyr 22 - Gly 536)
Q80X72-1

Poly-his

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 59.5 kDa. The protein migrates as 65-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per µg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- 20°C to -70°C for 12 months in lyophilized state;
- 70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Mouse LRRC15, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS




The purity of Mouse LRRC15, His Tag (Cat. No. LR5-M5225) is more than 90% and the molecular weight of this protein is around 68-92 kDa verified by SEC-MALS.

[Report](#)

Bioactivity-ELISA

Discounts, Gifts,
and more!





Immobilized Mouse LRRC15, His Tag (Cat. No. LR5-M5225) at 10 μ g/mL (100 μ L/well) can bind Samrotamab with a linear range of 1-10 ng/mL (QC tested).

Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGF β on activated fibroblasts (α SMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

